Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial

Phase 1

Completed

Conditions: Advanced Ovarian Cancer
Malignant Melanoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Procedure: Pembrolizumab
Biological: Tumor-Infiltrating Lymphocytes (TILs)
Biological: Interleukin-2 (IL-2)

First Posted Date: 2017-05-18

Last Posted Date: 2020-08-14

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 8

Registration Number: NCT03158935

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.

Phase 1

Conditions: B Cell Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: CD19 CART

First Posted Date: 2017-05-10

Last Posted Date: 2017-05-17

Lead Sponsor: Shenzhen Second People's Hospital

Target Recruit Count: 20

Registration Number: NCT03146533

Locations: 🇨🇳
The Second People's Hospital of Shenzhen, Shenzhen, Guangdong, China

Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers

Phase 1

Terminated

Conditions: Solid Tumor

Interventions: Drug: KITE-718
Drug: Cyclophosphamide
Drug: Fludarabine
Device: MAGE - A3/A6 Screening Test

First Posted Date: 2017-05-03

Last Posted Date: 2023-08-25

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 16

Registration Number: NCT03139370

Locations: 🇺🇸
Baylor Scott & White Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 9 locations

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Acute Leukemia
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Graft Versus Host Disease
Hodgkin Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Myelodysplastic Syndrome

Interventions: Drug: Busulfan
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Procedure: Hematopoietic Cell Transplantation
Other: Laboratory Biomarker Analysis
Drug: Melphalan Hydrochloride
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Quality-of-Life Assessment
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2017-04-25

Last Posted Date: 2024-01-09

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 38

Registration Number: NCT03128359

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Phase 1

Suspended

Conditions: Acute Lymphoblastic Leukemia
Recurrent Acute Lymphoblastic Leukemia
Chronic Myelomonocytic Leukemia
Myelodysplastic Syndrome With Excess Blasts
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Mixed Phenotype Acute Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Acute Myeloid Leukemia
Refractory Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study
Radiation: Pretargeted Radioimmunotherapy
Radiation: Total-Body Irradiation

First Posted Date: 2017-04-25

Last Posted Date: 2024-06-28

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 75

Registration Number: NCT03128034

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Hematopoietic/Lymphoid Cancer
Acute Myeloid Leukemia

Interventions: Procedure: Leukapheresis
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: CD33-CAR-T Cell Infusion

First Posted Date: 2017-04-24

Last Posted Date: 2019-11-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT03126864

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes

Phase 2

Active, not recruiting

Conditions: Myelodysplastic Syndromes
Acute Myeloid Leukemia

Interventions: Drug: Fludarabine
Drug: Busulfan
Drug: ATG
Radiation: Total Marrow Irradiation
Procedure: Stem Cell Product Infusion
Drug: Tacrolimus
Drug: Methotrexate

First Posted Date: 2017-04-19

Last Posted Date: 2024-07-25

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 38

Registration Number: NCT03121014

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Phase 2

Recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: ATG
Drug: fludarabine
Drug: cyclophosphamide
Radiation: Total body irradiation
Procedure: Stem cell infusion
Drug: Sirolimus
Drug: mycophenolate mofetil

First Posted Date: 2017-04-19

Last Posted Date: 2024-11-12

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 50

Registration Number: NCT03121001

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis

Phase 1

Active, not recruiting

Conditions: Secondary Myelofibrosis

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Glycosylated Recombinant Human G-CSF AVI-014
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mycophenolate Mofetil
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2017-04-18

Last Posted Date: 2024-10-30

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 22

Registration Number: NCT03118492

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

Phase 1

Conditions: Hematopoietic/Lymphoid Cancer
Refractory Chronic Lymphocytic Leukemia
B-cell Adult Acute Lymphoblastic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
B-cell Chronic Lymphocytic Leukemia

Interventions: Biological: anti-CD19 CAR-T
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2017-04-12

Last Posted Date: 2019-11-27

Lead Sponsor: First Affiliated Hospital of Wenzhou Medical University

Target Recruit Count: 20

Registration Number: NCT03110640

Locations: 🇨🇳
The First Affilicated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy